Trevena stock jumps more than 50% after FDA approves new pain drug
August 10, 2020 at 10:39 AM EDT
The FDA initially rejected Trevena's new drug application for Olinvyk in late 2018.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|